Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

3 Months Ended

Mar. 31, 2018

Note 9 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	March 31, 2018		December 31, 2017
Accrued clinical and development expenditure	$	10,212	$	10,065
Accrued employee expenses	4,084		6,592
VAT	458		5,741
Other accrued expenditure	3,829		3,944
Accrued capital expenditure	585		502
Other liabilities	482		357

	$	19,650	$	27,201